Shortening infusion time for high-dose methotrexate alters antileukemic effects: A randomized prospective: Clinical trial

Journal of Clinical Oncology

Volumn 29, Issue 13, 2011, Pages 1771-1778

  Mikkelsen, Torben S ^a,b,c   Sparreboom, Alex ^a,b,c   Cheng, Cheng ^a,b,c   Zhou, Yinmei ^a,b,c   Boyett, James M ^a,b,c   Raimondi, Susana C ^a,b,c   Panetta, John C ^a,b,c   Bowman, W Paul ^a,b,c   Sandlund, John T ^a,b,c   Pui, Ching Hon ^a,b,c   Relling, Mary V ^a,b,c   Evans, William E ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Cook Children's Hospital ^*  (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; PURINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CHILD; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; DRUG MEGADOSE; HUMAN; IN VIVO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURINE SYNTHESIS; RANDOMIZATION; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; METHOTREXATE; POLYGLUTAMIC ACID; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PURINES;

EID: 79955582395     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.5340     Document Type: Article

References (39)

1. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006
2. Chauvenet AR, Martin PL, Devidas M, et al: Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from Children's Oncology Group Study P9201. Blood 110:1105-1111, 2007 (Pubitemid 47281404)
3. Conter V, Valsecchi MG, Silvestri D, et al: Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: A multicentre randomised trial. Lancet 369:123-131, 2007 (Pubitemid 46073131)
4. Dordelmann M, Reiter A, Zimmermann M, et al: Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 20:444-450, 1998 (Pubitemid 29133199)
5. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium protocol 91-01. Blood 97:1211-1218, 2001 (Pubitemid 32183741)
6. Clarke M, Gaynon P, Hann I, et al: CNSdirected therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 21:1798-1809, 2003 (Pubitemid 46646217)
7. Dervieux T, Brenner TL, Hon YY, et al: De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 100:1240-1247, 2002 (Pubitemid 34864278)
8. Masson E, Relling MV, Synold TW, et al: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: A rationale for high-dose methotrexate. J Clin Invest 97:73-80, 1996
9. Sorich MJ, Pottier N, Pei D, et al: In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 5:e83, 2008
10. Barredo JC, Synold TW, Laver J, et al: Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564-569, 1994 (Pubitemid 24215957)
11. Rots MG, Pieters R, Peters GJ, et al: Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 93: 1677-1683, 1999 (Pubitemid 29102496)
12. Kager L, Cheok M, Yang W, et al: Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 115:110-117, 2005 (Pubitemid 40385511)
13. Zhang L, Taub JW, Williamson M, et al: Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clin Cancer Res 4:2169-2177, 1998 (Pubitemid 28415664)
14. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322, 2000 (Pubitemid 30428458)
15. Synold TW, Relling MV, Boyett JM, et al: Blast cell methotrexate- polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996-2001, 1994
16. Brugieres L, Le Deley MC, Rosolen A, et al: Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL group. J Clin Oncol 27:897, 2009
17. Woessmann W, Seidemann K, Mann G, et al: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 105:948, 2005
18. Wolfrom C, Hartmann R, Fengler R, et al: Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 11:827-833, 1993 (Pubitemid 23146075)
19. Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009
20. Zaza G, Yang W, Kager L, et al: Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood 104: 1435-1441, 2004 (Pubitemid 39166522)
21. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide. Los Angeles, CA, Biomedical Simulations Resource, 1990
22. Panetta JC, Yanishevski Y, Pui CH, et al: A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 50:419-428, 2002 (Pubitemid 35440531)
23. French D, Yang W, Cheng C, et al: Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 113:4512-4520, 2009
24. Kamen BA, Winick N: Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzymol 122:339-346, 1986 (Pubitemid 16017526)
25. Masson E, Synold TW, Relling MV, et al: Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia 10:56-60, 1996 (Pubitemid 26052980)
26. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 94: 496-497, 1999
27. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data, New York, NY, Wiley New York, 1980
28. Galpin AJ, Schuetz JD, Masson E, et al: Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human Blineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 52:155-163, 1997 (Pubitemid 27318631)
29. Hum MC, Smith AK, Lark RH, et al: Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro. Pharmacotherapy 17:1260-1266, 1997 (Pubitemid 27518038)
30. Keefe DA, Capizzi RL, Rudnick SA: Methotrexate cytotoxicity for L5178Y/Asn-lymphoblasts: Relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42:1641, 1982
31. Pinedo HM, Chabner BA: Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep 61:709-715, 1977 (Pubitemid 8156485)
32. Panetta JC, Sparreboom A, Pui CH, et al: Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 6:e1001019, 2010
33. Bökkerink JPM, De Abreu RA, Bakker MAH, et al: Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37:2329-2338, 1988
34. Bökkerink JPM, Bakker MAH, Hulscher TW, et al: Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37:2321-2327, 1988
35. Hooijberg JH, Broxterman HJ, Kool M, et al: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535, 1999 (Pubitemid 29269093)
36. Loh ML, Goldwasser MA, Silverman LB, et al: Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107:4508-4513, 2006 (Pubitemid 43801379)
37. Pui CH, Sandlund JT, Pei D, et al: Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290:2001-2007, 2003
38. Rubnitz JE, Wichlan D, Devidas M, et al: Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 26:2186-2191, 2008
39. Winick N, Martin PL, Devidas M, et al: Delayed intensification (DI) enhances event-free survival (EFS) of children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG). Blood 110, 2007 (abstr 583)